NEW YORK, Jan. 21 (GenomeWeb News) - Branford, Conn.-based Cellular Genomics today announced the initial closing on a $22.3 million Series C round of venture-capital financing.
Lilly BioVentures, and has been joined by new investors Coastview Capital and Emerging Technology Partners, as well as existing investors including Connecticut Innovations, Flagship Ventures, MPM Capital, and Vector Fund Management, the company said.
The company said it will use the funds to push its drug-discovery programs in cancer, angiogenesis, and autoimmune/inflammatory diseases into clinical development and to achieve key clinical milestones.
Cellular Genomics is developing a chemical genetics platform (Analog Sensitive Kinase Allele, or ASKA, technology) to discover and develop kinase and other signal transduction inhibitors for multiple clinical indications.